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Abstract
Background: Tuberculosis (TB) is one of the most prevalent infectious diseases affecting millions worldwide. The
currently available anti-TB drugs and vaccines have proved insufficient to contain this scourge, necessitating an
urgent need for identification of novel drug targets and therapeutic strategies. The disruption of crucial protein-protein
interactions, especially those that are responsible for virulence in Mycobacterium tuberculosis – for example the ESAT-6:
CFP10 complex – are a worthy pursuit in this direction.
Methods: We therefore sought to improvise a method to attenuate M. tuberculosis while retaining the latter’s antigenic
properties. We screened peptide libraries for potent ESAT-6 binders capable of dissociating CFP10 from ESAT-6. We
assessed the disruption by a peptide named HCL2, of the ESAT-6:CFP10 complex and studied its effects on mycobacterial
survival and virulence.
Results: We found that HCL2, derived from the human cytochrome c oxidase subunit 3 (COX3) protein, disrupts ESAT-6:
CFP10 complex, binds ESAT-6 potently, disintegrates bacterial cell wall and inhibits extracellular as well as intracellular
mycobacterial growth. In addition, an HCL2 expressing M. tuberculosis strain induces both Th1 and Th17 host protective
responses.
Conclusions: Disruption of ESAT-6:CFP10 association could, therefore, be an alternate method for attenuating
M. tuberculosis, and a possible route towards future vaccine generation.
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Background
Tuberculosis (TB) remains the leading cause of infectious
disease-related deaths worldwide. There are an estimated
8.5-9.2 million cases and 1.2-1.5 million deaths caused by
Mycobacterium tuberculosis (M.tb) each year [1]. One-
third of the global population is infected with the latent
form of TB, a scenario translating into an enormous reser-
voir for a future pandemic. BCG, the only available
vaccine, provides significant protection against dissemi-
nated and tubercular meningitis, but has very little or no
efficacy against adult pulmonary TB [2]. We have earlier
shown that an optimum host protection against TB
requires both Th1 and Th17 responses [3]. BCG induces
Th1 response, but fails to induce Th17 response in the
lung, a factor mostly responsible for the inferior efficacy of
BCG [3,4]. Considerable efforts have been made to generate
recombinant BCG but with little headway [5,6]. On the
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other hand, the currently available anti-TB chemotherapy,
DOTS, is lengthy, consists of multiple antibiotics that cause
severe hepatotoxicity and is effective in only 50% of MDR-
TB cases [7,8]. Therefore, identification of novel therapeutic
strategies is urgently needed.
A promising approach can be the targeting of important
protein-protein interactions within the pathogen, with an
emphasis on those proteins that are the source of myco-
bacterial virulence. As of now, there exist no peptides or
small molecules that specifically target bacterial virulence
factors. Such moieties can conveniently be used along
with conventional drugs to improve TB chemotherapy
and in combating multi-drug resistance [9]. Quite often
virulence is dependent on protein-protein interactions, an
area that is as yet unexplored for the development of ad-
vanced therapeutics. Recently, it has been shown that
ESAT-6, a protein derived from the region of difference
(RD-1), plays a critical role in mounting Th17 responses
in the lung [3,4]. As stated earlier, we showed that the vac-
cine strain of BCG lacks the RD-1 region and is therefore
unable to generate Th17 responses. Similarly, the RD-1
mutant of H37Rv also fails to induce Th17 responses [3].
Although RD-1 recombinant BCG generates both Th1
and Th17 responses, this strain is unsuitable as a vaccine
because RD-1 addition makes BCG virulent [10]. It was,
therefore, our aim to elucidate the role of interaction be-
tween RD-1 components and their potential therapeutic
interventions.
In M.tb, ESAT-6 and CFP10 proteins are encoded by
the RD1 region (9.5 kb in length comprising 9 genes –
part of ESX1 secretion system), and secreted as a tight 1:1
heterodimer with a dissociation constant of 1.1 × 10−8 M
[11,12]. It is well known that the ESAT-6:CFP10 complex
plays pivotal role in the pathogenesis of TB. Indeed, dele-
tion of ESAT-6 or RD1 locus attenuates M.tb and dramat-
ically reduces vaccine efficacy of the attenuated mutants
[3,13]. The many crucial roles of ESAT-6 include mem-
brane lytic activity due to its helix-turn-helix structure
and hydrophobic nature that helps mycobacteria escape
from phagolysosome and spread [14], as well as macro-
phagial aggregation and granuloma formation, leading to
intercellular bacterial dissemination [15]. It is becoming
increasingly clear that ESAT-6 is decisive for the virulence,
pathogenesis, and survival of M.tb.
Therefore, to understand whether in vivo disruption of a
protein complex that involves ESAT-6 as a primary compo-
nent has an effect on the pathogenesis of M. tuberculosis,
we screened peptides that bind to ESAT-6 with potent
affinity and are capable of dissociating CFP10 from
ESAT-6. We report here the strong binding capability
of a peptide named HCL2 (amino acid sequence: ESTY
QGH-HTPPVQKGLRYGIILFITSEVFFFAGFF*), a frag-
ment from human mitochondrial protein COX3, with
ESAT-6. We assessed the disruption by HCL2 of the
ESAT-6:CFP10 complex by employing a Bacterial Three-
Hybrid system recently developed in our laboratory [16]
and report a direct correlation in HCL2 expression and
ESAT-6:CFP10 disruption. We determined the effects of
exogenous and endogenous HCL2 on the growth of M.tb
and observed significant bacteriocidal effects and changes
in cellular and colony morphology. Furthermore, we re-
port the generation of an HCL2-expressing H37Rv strain,
infection by which induces IL-12 as well as IL-6 produc-
tion in macrophages, which are the polarizing cytokines
for Th1 and Th17 differentiations respectively. Therefore
the present study extends our earlier studies regarding
BCG and Th17 responses [3], and establishes as a proof of
concept, the development of an alternative strain for
therapeutic intervention. In addition, HCL2 could also
serve as a template for designing new and improved
peptide-based therapeutics against TB.
Methods
Antibodies and reagents
We used rabbit anti-ESAT-6 antibody (Abcam, Cambridge,
MA), mouse anti-His6X antibody (Sigma-Aldrich, St. Louis
MA), anti-FLAG antibody (Sigma-Aldrich, St. Louis MA),
HRP conjugated anti-mouse IgG (Bio-rad, Hercules, CA),
anti-rabbit FITC conjugated secondary antibody (Jackson-
ImmunoResearch, West Grove, PA) and anti-mouse Texas
Red secondary antibody (Jackson-ImmunoResearch, West
Grove, PA) for in vitro studies. For in vivo studies, anti-
CD4 (clone: GK1.5)-FITC, −PerCP-Cy5 or -APC, anti-CD8
(clone: 53–6.7)-FITC, −PerCP-Cy5 or -APC, anti-CD44
(clone: IM7)-APC, anti-Brdu (clone: Bu20a)-PE, anti-
CD11b (clone: M1/70)-APC, anti-CD11c (clone: N418)-
APC, 7AAD, anti-IFN-γ (clone: XMG1.2)-APC, anti-IL-17
(clone: TC11-18H10.1)-PE, anti-IL-4 (clone: 11B11)-PE,
anti-IL-6 (clone: MPS-20 F3)-PE, anti-IL-12 (clone:
C15.6)-PE, anti-IL-22 (clone: Poly5164)-PE, anti-IL-10
(clone: JES5-16E3)-PE, anti-IL-9 (clone: MH9A4)-PE, anti-
TNF-α (clone: MP6-XT22)-PE, (all from Biolegend, USA)
and anti-CD69 (clone: H1.2 F3)-PE (from eBiosciences,
USA) were used.
Mice
BALB/c female mice at 6–8 weeks of age were used
throughout this study, following institutional ethical
committee guidelines. All animal experiments were con-
ducted in accordance with guidelines approved by the
Institutional Animals Ethics Committee of ICGEB, New
Delhi, India and Department of Biotechnology (DBT),
Government of India. Mice were housed under barrier
conditions in a Biosafety Level III laboratory.
Bacterial two-hybrid studies
Bacteriomatch™ system was used as described earlier
[16,17]. Two colonies each from HCL2pTRGnn + ESAT-
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6pBTnn, positive and negative, were grown in cultures
and patched on X-gal indicator plate. Interactions were
validated by liquid β-Galactosidase assay and compared
with well-established mycobacterial interaction between
ESAT-6 and CFP10 (ESAT-6pBTnn +CFP10pTRGnn).
In vitro Far-Western Dot Blot analysis
For Far-Western Dot Blot assay, ESAT-6-FLAG was puri-
fied by ion-exchange chromatography. Briefly, E. coli BL21
(DE3) cells harboring flagesat6pET28a were subjected to
IPTG induction and cells were harvested, lysed in de-
naturing condition. Clear supernatant was allowed to bind
on DEAE-sepharose (Amersham) followed by washing
with lysis buffer and the resin bound proteins were eluted
using a gradient of NaCl from 0 M to 1 M, prepared in
lysis buffer. Purified protein was refolded by sequential
dialysis against PBS with decreasing concentration of urea.
The interaction between ESAT-6-FLAG and HCL2-His6X
(commercially synthesized from GenScript, Hong Kong)
was determined using a protocol reported previously [16].
An unrelated protein ED3-His6X (sequence given in
Additional file 1: Figure S1) was used as a negative control.
CFP10-His6X and ESAT-6-FLAG were used as positive
controls.
Cloning of HCL2 in pMTSA vector
The ORF encoding HCL2 peptide was amplified from ori-
ginal lung cDNA library clone using 5’-AAGGATCC-
TACGTAAGAATTCGGCACGAG-3’ and 5’-AAGGATC
CTACGTAGAAAA ATCCTGCGAAGAAAA-3’ as for-
ward and reverse primers respectively. The gene was
cloned in a SnaBI site in an arabinose-inducible three-
hybrid vector as previously described [16]. Expression of
HCL2-His6X was analyzed on Tricine-SDS PAGE and
Western Blotting was done using Anti-His6X antibodies.
Bacterial Three-Hybrid and arabinose gradient liquid
β-Galactosidase assay
Bacterial Three-Hybrid studies were carried out as
described earlier [16]. To study the correlation between
disruption of the ESAT-6:CFP10 interaction and in vivo
expression levels of HCL2, an Arabinose gradient liquid β-
Galactosidase assay was performed. The experiment was
carried out in triplicates by varying L-arabinose concen-
tration ranging from 0 to 1%. Western Blotting was done
with increasing concentration of L-arabinose (0-1%), to
show the gradual increase in HCL2-His6X induction corre-
sponding to decrease in β-Galactosidase activity.
HCL2 cloning in a mycobacterial shuttle vector
The ORF expressing HCL2 peptide was cloned in myco-
bacterial constitutive expression vector pVV16 and
pVVGFPHis6X and used to electroporate H37Rv electro-
competent cells, as described earlier [17].
Effect of HCL2 on M. tuberculosis growth
We examined the effects of HCL2 peptide on M.tb growth
by using two methods. First, by electroporating
HCL2pVV16 (H37Rv/HCL2; strain expressing HCL2-
His6X) and secondly by adding HCL2-His6X peptide to the
culture exogenously at a final concentration of 15 μg/ml
(H37Rv +HCL2). HCL2 was cloned in mycobacterial con-
stitutive expression vector pVV16 as described earlier
[17]. Cultures were inoculated in triplicates each for
H37Rv/HCL2, H37Rv +HCL2, H37Rv/pVV16 (strain hav-
ing only plasmid control), ΔRD1, H37Rv/GFP, H37Rv +
DL1 and H37Rv and assessed spectrophotometrically for
18 days at 630 nm. H37Rv was added with equivalent
amount of Milli-Q water used to dissolve the peptide
HCL2-His6X. A higher concentration of HCL2-His6X was
not used due to precipitation of the peptide at concentra-
tions > 15 μg/ml. Strain lacking RD1 region (ΔRD1; kind
gift of Prof. David R. Sherman), H37Rv expressing GFP
(H37Rv/GFP), and addition of an unrelated peptide
(sequence given in Additional file 1: Figure S1) DL1
(H37Rv + DL1) were used as controls. Another ESAT6
binding peptide, SL3, from our previous studies [16] was
also analyzed for its effects on mycobacterial growth dur-
ing this study (unpublished results).
Effect of HCL2 on cellular and colony morphology
Electron microscopy was carried out to examine the effect
of endogenous or exogenous HCL2 on cellular morph-
ology of M.tb. H37Rv/HCL2, H37Rv + HCL2, H37Rv,
ΔRD1 and H37Rv/pVV16 cells were fixed by treating with
2% paraformaldehyde solution and adsorbed on a
300 mesh copper grid and air dried. Samples were stained
with 1% uranyl acetate followed by photography using a
FEI Tecnai 12 Electron Microscope. H37Rv, H37Rv/
pVV16 and ΔRD1 strains were used as controls. In
addition, colony morphology of H37Rv/HCL2 strain was
observed on 7H11 plates and colony texture was com-
pared with H37Rv.
Infection of THP-1 cells by M. tuberculosis in presence of
HCL2 peptide
Approximately 12,000/well phorbol-12-myristate-13-acet-
ate (Sigma, USA) activated THP-1 cells in a 96 well flat
bottom tissue culture plate were infected with M.tb
H37Rv/HCL2 at an MOI of 1:10 using a protocol de-
scribed previously [18]. Cells were harvested, lysed and
plated on 7H11 agar at 0, 24, 48 and 72 hours and CFU
counts determined. For effects of exogenous HCL2-His6X
(H37Rv + HCL2), peptide was added to RPMI media at a
final concentration of 15 μg/ml and this media was added
to H37Rv infected tissue-culture plates at 0 hours and
changed after every 24 hours till 72 hours. H37Rv, H37Rv/
GFP, H37Rv + DL1 and ΔRD1 were used as control strains
to infect THP-1 cells. In this experiment, SL3 peptide was
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also analyzed for its effects on intracellular survival
(unpublished results).
Mice infection with H37Rv/HCL2, CFU counts and
immunology
BALB/c mice were infected with ~150 CFU of H37Rv
and H37Rv/HCL2 using an aerosol chamber. Mice were
sacrificed at different time points and cytokine profile and
T lymphocytes proliferation were assessed as described
earlier [19]. For CFU counts lung and spleen were har-
vested at different time points and processed as described
previously [19].
Statistical analysis
All experiments were repeated thrice and in triplicates.
Mean values were calculated with standard deviation
(STDEV) unless stated otherwise. For all statistical ana-
lyses Student's T-test was performed to compare two
groups; p < 0.05 was considered significant.
Results
HCL2 interacts with ESAT-6 in vitro
The genes coding for HCL2 and ESAT-6 were cloned sep-
arately in the bacterial two-hybrid vectors pTRGnn and
pBTnn, and the vectors used to transform the two-hybrid
strain. HCL2pTRGnn + ESAT-6pBTnn (‘+’ indicates pres-
ence of both plasmids in the two-hybrid bacterial strain)
showed a characteristic blue color comparable to the posi-
tive control ESAT-6pBTnn + CFP10pTRGnn, while ESAT-
6pTRGnn + pBTnn (negative control) was distinctly white
(Figure 1A). Liquid β-Galactosidase assay indicated that
HCL2pTRGnn + ESAT-6pBTnn has comparable binding
Figure 1 HCL2 binds with ESAT-6 and disrupts the ESAT-6:CFP10 heterodimeric complex. (A) Agar plate showing co-transformants: a – ‘white’
negative control pBTnn + ESAT-6pTRGnn; b – interacting clone ESAT-6pBTnn + HCL2pTRGnn; c – ‘blue’ positive control CFP10pTRGnn + ESAT-6pBTnn.
(B) Interactions between ESAT-6pBTnn + HCL2pTRGnn and ESAT-6pBTnn + CFP10pTRGnn were found comparable by Liquid β-Galactosidase assay.
Experiments were repeated thrice and similar observations were made. All readings were found statistically significant by applying Student’s T-test.
(*P < 0.05) (C) HCL2-His6X interacts with ESAT-6-FLAG in vitro. Experiment was repeated thrice and each time positive interaction was observed
between HCL2-His6X and ESAT-6-FLAG. (D) Disruption of ESAT-6:CFP10 interaction by HCL2 using the three-hybrid system. Three separate colonies from
each triple co-transformants plate were picked and patched. a – (ESAT-6pBTnn-CFP10pTRGnn) + HCL2pMTSA; b – (ESAT-6pBTnn-CFP10pTRGnn) + pMTSA.
–ARA represents plate without Arabinose induction while + ARA represents plate with Arabinose induction. Experiments were repeated thrice and similar
observations were made. (E) Bacterial Three-Hybrid results were also corroborated by Arabinose Gradient Liquid β-Galactosidase Assay. Experiment was
repeated thrice in triplicates. All readings were found statistically significant by applying Student’s T-test (*P < 0.05).
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strength to ESAT-6pBTnn +CFP10pTRGnn (Figure 1B).
Far-Western Dot Blot revealed positive interaction between
ESAT-6-FLAG and HCL2-His6X proteins (Figure 1C). ED3-
His6X, an unrelated protein, showed no interaction.
Loading controls were provided by applying ponceau
staining to nitrocellulose membrane just after spotting
primary proteins.
HCL2 can disrupt the ESAT-6:CFP10 heterodimeric complex
Bacterial three-hybrid studies demonstrated that presence
of HCL2 peptide in a cell expressing ESAT-6 and CFP10
changes the colony color from blue to white, thereby
disrupting ESAT-6:CFP10 interaction (Figure 1D). An
arabinose gradient liquid β-Galactosidase assay exhibited a
concomitant decrease in β-Galactosidase activity with a
proportionate HCL2 expression, observed by Western
blotting with Anti-His6X antibodies (Figure 1E), confirming
a robust expression of HCL2-His6X peptide in three-hybrid
experiments.
HCL2 inhibits mycobacterial growth in axenic cultures
HCL2 showed significant levels of expression inside
H37Rv cells as indicated by constitutive expression of
HCL2-GFP-His6X in H37Rv/HCL2GFP when observed by
confocal microscopy (Figure 2A). 91.53% of H37Rv/
HCL2GFP cells were found to be expressing HCL2
(Additional file 2: Figure S2). We studied mycobacterial
growth in liquid cultures and observed dramatically
Figure 2 HCL2 inhibits mycobacterial growth in axenic cultures. (A) Expression of peptide HCL2-His6X in H37Rv cells. Significant reductions were
observed in mycobacterial growth in the presence of HCL2 as revealed by growth curves. Reduction with both endogenous (B) and exogenous
(C) HCL2 was found statistically significant by applying Student’s T-test (*P < 0.05).
Samuchiwal et al. BMC Infectious Diseases 2014, 14:355 Page 5 of 11
http://www.biomedcentral.com/1471-2334/14/355
reduced growth in presence of both endogenous as well as
exogenous HCL2 in comparison to wild type H37Rv and
control strains (Figure 2B & 2C).
HCL2 affects cellular and colony morphology
It is highly likely that accumulation of ESAT-6 within
mycobacterial cells may be toxic. To directly observe the
effect of HCL2 in M.tb, we performed electron microscopy
experiments. We found that HCL2 expressing strain is fee-
ble and often possesses a porous membrane (indicated by
arrows) (Figure 3A). To further test if exogenously added
HCL2 is sufficient to alter M.tb cell viability and cell wall
damage as observed in HCL2-recombinant H37Rv, we
treated M.tb with HCL2 peptide. Interestingly, we ob-
served similar cell wall disintegration (indicated by arrows)
(Figure 3A). Representative images have been provided
(Figure 3A), and at least 10 fields were visualized from dif-
ferent grid areas and percentages of cell deformations were
calculated (Additional file 3: Figure S3). Furthermore,
colony morphology of H37Rv/HCL2 strain was also ob-
served as appearing smooth when compared to the H37Rv
(Figure 3B). Colonies from 4 different plates were observed
and representative photographs have been provided.
HCL2 inhibits mycobacterial growth in THP-1 cell line
It is clear that expression of HCL2 in M. tuberculosis ren-
ders slow growth in liquid cultures. This however does
not reflect the status of virulence. Indeed, some of the
drug resistant and mutant strains grow slower than the
parent H37Rv [20]. In an intracellular survival experiment,
we observed that uptake of both H37Rv and H37Rv/HCL2
was similar by THP-1 cells. However, a drastic reduction
of bacterial load after 72 hours was noticed in the mutant
HCL2 strain. The control strains such as H37Rv/pVV16,
H37Rv/GFP and ΔRD1 continued to grow as reported
previously (Figure 3C). Similar reductions in CFU counts
were observed when HCL2 was added exogenously over
infected THP-1 cells (Figure 3C). Any possible cytotoxic
Figure 3 HCL2 disintegrates bacterial cell wall, changes colony texture and inhibits intracellular growth. (A) Transmission electron
micrographs of mycobacterial cells depicted effects of HCL2 on cell wall integrity and cell shape. (B) Representative photographs exhibiting the
difference in colony morphology and colony surface texture between H37Rv and H37Rv/HCL2. (C) Significant reductions were found in
mycobacterial counts inside THP-1 in the presence of endogenous and exogenous HCL2 peptide. All experiments were conducted in triplicates
and repeated at least thrice. (t = 0) defines the time at the beginning of phagocytosis. All readings were found statistically significant by applying
Student’s T-test (*P < 0.05).
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effects of HCL2 on THP-1 cells were studied by MTT
assay at 0, 24, 48 and 72 hours after addition of 15 μg/ml
HCL2 peptide. No cytotoxicity was observed (data not
shown). These observations indicated to us that HCL2 po-
tentially disrupts virulence. It is important to notice here
that the inhibition of intracellular growth is similar to that
of the avirulent ΔRD1 mutant, suggesting that disruption
of ESAT-6:CFP10 leads to a similar attenuation outcome.
M. tuberculosis H37Rv/HCL2 mounts host protective
immune response
Our aim was to disrupt virulence but at the same time re-
tain the antigenic property inherent in H37Rv. While it is
clear that the recombinant strain is indeed prone to faster
clearance by the macrophages, for a robust vaccine effi-
cacy, adaptive immunity in the form of both Th1 and
Th17 responses is required. Therefore, we tested whether
HCL2-expressing M. tuberculosis strain can mount Th1
and Th17 responses. We infected BALB/c mice to deter-
mine the bacterial burden at different time-points as well
as mounting the M. tuberculosis antigen-specific immune
responses. We observed a significant difference in bacter-
ial burden 8 days post-infection in mice (BALB/c) model
between H37Rv and H37Rv/HCL2 strains. There was no
detectable bacillary load 12 and 16 days post-infection
(Figure 4A) in H37Rv/HCL2 infected mice. Interestingly,
we found that clearance of HCL2 recombinant strain is
much faster than that of parent H37Rv or ΔRD1 strain.
This could either be because a non-functioning ESAT-6:
CFP10 complex attenuates this strain. This observation
indicates that the recombinant strain H37Rv/HCL2 is
avirulent. It has been shown in various studies that strong
Figure 4 HCL2 peptide expressed in M. tuberculosis H37Rv reduces bacterial burden and activates T-cells. (A) Bacterial burden in lungs at
day 16 in H37Rv, ΔRD1 and H37Rv/HCL2 infected mice (*p < 0.05). Data shown here is a representative of two independent experiments. Each CFU
experiment has been carried out in triplicates (6 mice per experiment). (B) Enhanced T cell proliferation in response to M. tuberculosis bacterial protein
lysate (Complete Soluble Antigen) (*p < 0.05). (C) T cell proliferation in vivo by Brdu incorporation. Data shown here is representative of three
independent experiments with six mice in each group and represents the mean ± STDEV values. (D) The percentage of cells expressing CD44 and
CD69 among CD4+ T cells is shown in the dot-plot with mean ± STDEV. CD44 and CD69 expression by CD4+ splenocytes was also found to be
significantly higher in H37Rv/HCL2 infected mice than H37Rv infected mice. Data shown here are representative of three independent experiments with
six mice in each group.
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attenuation of the strain leads to decreased bacterial counts
in lungs and spleen [20]. M. tuberculosis antigen-specific
immune response was determined in infected animals by
examining proliferation of splenocytes stimulated with M.
tuberculosis Complete Soluble Antigen (CSA) 10 days
post-infection. A dramatic enhanced antigen-specific hyper
proliferatve response was observed in animals infected with
H37Rv/HCL2 as compared to that of H37Rv (Figure 4B).
In vivo proliferation of T cells in Splenocytes and Lung
T cells was tested by Brdu incorporation and we noticed
H37Rv/HCL2 infected animal had increased T cell prolif-
eration (Figure 4C). We examined CD69 and CD44
expression in CD4+ populations and found significantly
higher expression (Figure 4D). To study further the im-
mune responses, we focused our attention on CD4, CD8,
NK1.1 and Professional APCs. It was observed that CD4,
CD8, CD11b and CD11c numbers (Figure 5A & 5B) were
dramatically higher compared to the control animals that
were infected with H37Rv. To check the cytokine milieu in
H37Rv/HCL2 and H37Rv infected mice, we isolated the
cells from spleen and cultured them with PMA, Ionomycin
and M. tuberculosis lysate (CSA) in appropriate concentra-
tions overnight. Subsequently, after 6 hrs of BFA treatment,
we carried out intracellular staining for IL-4, IFN-γ, IL-17,
IL-9, IL-10, IL-12, TNF-α, IL-6 and IL-22. We found no
difference in IL-10 but obtained a significant up-regulation
of IL-4, IFN-γ, IL-17, IL-9, IL-12, TNF-α, IL-6 and IL-22
(Figure 5C) secretion in H37Rv/HCL2 infected mice. These
data indicated that expression of HCL2 in H37Rv attenu-
ates its virulence. However, they retain antigenic property
to mount immune response similar to that of virulent
strain H37Rv. In all experiments, we used ΔRD1 as a con-
trol, which is known to lose its antigenic capacity to mount
host protective immune responses. Clearly, our study dem-
onstrated that, although HCL2 recombinant strain was
attenuated, it still retained superior antigenic property and
mounted a better host immune response than ΔRD1.
HCL2 is not toxic to host cells
We were intrigued that expression of HCL2 not only at-
tenuates virulence, but also renders slow bacterial growth
in liquid culture and disintegrates bacterial cell wall. This
Figure 5 HCL2 peptide expressed in M. tuberculosis H37Rv enhances expression of helper T-cells and prime APCs. (A) The percentage of
splenic T lymphocytes in H37Rv/HCL2, ΔRD1 and H37Rv infected mice expressing CD4 and CD8 is shown in the bar diagram with mean ± STDEV
and Student’s T-test (*p < 0.05). (B) Increased number of Professional APCs was observed in H37Rv/HCL2 infected mice as compared to H37Rv and
ΔRD1 infected mice at day 10 after infection. The percentage of cells expressing CD11B and CD11C is shown in the bar diagram with mean ± STDEV
and Student’s T-test (*p < 0.05). (C) Total cytokine production by splenocytes is shown by bar diagram. Data shown with mean ± STDEV and Student’s
T-test was applied for estimating significance between two parameters (*P < 0.05).
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raises the question whether HCL2 is itself toxic. To exam-
ine this possibility we tested HCL2 on host cells. We did
not find any toxicity in mice lung lymphocytes (Figure 6).
Furthermore, addition of HCL2 had no effect on the
growth of Escherichia coli (data not shown). Early apop-
totic events were also ruled out on murine macrophages
in presence of HCL2 (Additional file 4: Figure S4A).
Therefore, toxicity towards bacilli by HCL2 is rather
specific.
Discussion
ESAT-6 is one of the major secretory proteins of M.tb and
plays a critical role in mycobacterial pathogenesis. In
extracellular milieu, it modulates the host immune re-
sponse and facilitates bacterial spread and dissemination
among macrophages and dendritic cells [14,15,21-24].
Furthermore, a large body of literature suggests that ef-
fective protection against TB requires both Th1 and Th17
responses from host [3-6]. Role of mycobacterial secretory
protein ESAT-6, a protein derived from the region of dif-
ference (RD-1), in mounting Th17 responses in the lung
has been established earlier by us [3]. The inability of the
only known vaccine, BCG, to mount Th17 response can
be attributed to the absence of region RD-1 that codes for
ESAT-6 and its cognate secretion system. This raises the
possibility that RD-1 substituted BCG could serve as a
better vaccine. Indeed, immune responses induced by RD-
1 recombinant BCG provide superior vaccine efficacy.
However, RD-1 substitution in BCG makes the recombin-
ant strain gain virulence, and thus is not suitable for
vaccine implication [10,25-27].
We aimed to identify a novel peptide that can incapaci-
tate ESAT-6 and counter its debilitating functions on host
system. In our effort to disrupt virulence, we chose to
screen peptides from human origin so as to avoid un-
wanted immune response. The study presented here has
demonstrated that HCL2, a peptide from human COX3
protein, strongly binds ESAT-6, disrupts ESAT-6:CFP10
association, and inhibits the growth of M.tb in axenic
cultures and in macrophages and mice. This is the first ex-
ample of a peptide disrupting a known protein-protein
interaction. HCL2 is part of a seven-bundle helix of COX3
and homology-based modeling shows that it forms a hel-
ical structure that interacts with ESAT-6, possibly through
hydrophobic interactions – a likely scenario as ESAT-6 it-
self forms a helix-turn-helix and interacts with the helical
arm of CFP10 due to hydrophobic interactions (Additional
file 4: Figure S4B).
HCL2 disrupted the strong heterodimeric interaction
between ESAT-6 and CFP10 in vivo and led to significant
reduction in extracellular and intracellular mycobacterial
growth. Incapacitation of ESAT-6 by HCL2 could hinder
the cell-to-cell spread, as also indicated by effects of
HCL2 on intracellular mycobacterium. Therefore, HCL2
has the potential to inhibit M.tb spread and pathogenesis
inside macrophages.
Interestingly, our electron microscopy data showed
distinct degeneration of cell wall and changes in the cell
morphology in presence of HCL2 peptide, both endogen-
ous and exogenous. Likewise, mycobacteria expressing
HCL2 formed a distinctly smoothened colony. To rule out
the general cytotoxic nature of HCL2, its treatment of
Figure 6 HCL2 is non-toxic to mice. Cell death in both CD4+ as well as CD8+ lung lymphocytes in H37Rv/HCL2, ΔRD1 and H37Rv infected mice.
Data showed in Contour plot with mean ± STDEV.
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uninfected THP-1 cell lines and E. coli with HCL2 had no
effect, suggesting that it is rather specific to M.tb (data not
shown); in addition H37Rv/HCL2 infections were non toxic
to mice alveolar lymphocytes and peritoneal macrophages.
One possibility is that HCL2 binds and disrupts the se-
cretion system at a location on the bacterial cell surface
that harbors the ESAT-6:CFP10 complex, leading to accu-
mulation of toxic material inside the cells resulting in
weak growth. This hypothesis is further strengthened by
the fact that treatment of H37Rv with unrelated peptides
had no effect on the growth. Notably, intracellular survival
of the pathogen inside human macrophagial THP-1 cell
line was also hindered by HCL2. Mycobacterial strain ex-
pressing HCL2 was cleared surprisingly fast from the cells
and similar effects were observed when cells infected with
wild type H37Rv were treated with HCL2 exogenously.
To establish the type of immune response raised by
HCL2-expressing H37Rv (H37Rv/HCL2), BALB/c mice
were infected with H37Rv/HCL2 and mycobacterial
survival and immune response were studied. The HCL2
expressing strain was cleared in two weeks duration while
H37Rv continued to grow exponentially showed the nor-
mal growth defect. H37Rv/HCL2 enhanced T cell, macro-
phage and dendritic cells proliferation and led to activation
of CD4+ populations. The cytokine milieu in H37Rv/HCL2
showed significant up-regulation of IFN-γ, IL-17, IL-9, IL-
12, TNF-α, IL-6 and IL-22. It is clear that H37Rv/HCL2 in-
duces host protective immune responses. It was important
to find out whether there was a potent enhancement in IL-
17, IL6 and IL-22 cytokines, the key regulators of Th17
response, as it is widely believed that Th1 and Th17 re-
sponses play important roles in host protective immunity,
unlike BCG that is unable to mount a Th17 response. In-
deed, we observed that the recombinant strain mounts a
strong Th1 and Th17 host protective response, we believe
ultimately responsible for the accelerated clearance of this
recombinant strain.
This is the first study demonstrating the ability of a
novel peptide HCL2 to disrupt the ESAT-6:CFP10 hetero-
dimeric complex and significantly affect growth of both
extracellular and intracellular bacteria, as well as cellular
morphology and colony texture on solid media. Concomi-
tantly, in preclinical mouse model system, HCL2 has
shown significant reduction in mycobacterial infection
and strong protective immune response. This study was
aimed as a proof-of-concept validation and long-term
vaccine efficacy experiments are currently the focus of our
laboratories.
Conclusions
We have demonstrated that disruption of ESAT-6:CFP10
attenuates virulence in M. tuberculosis rendering faster
clearance in mice. Unlike BCG or ΔRD1, HCL2 recombin-
ant M. tuberculosis retains better host protective immune
responses. The present study lays the foundation for a
possible BCG alternative and thus deserves attention and
testing for eventual human application. Further studies,
involving direct comparison with BCG, will throw more
light on this possibility, while at the same time, separately;
HCL2 offers a tantalizing template for the synthesis of
anti-TB peptidomimetic molecules.
Additional files
Additional file 1: Figure S1. Sequences of control peptides ED3-His6X
and DL1, used as ‘unrelated peptide controls’ in this study. Sequence of
another ESAT-6 binding peptide named SL3 has also been provided
(unpublished results).
Additional file 2: Figure S2. HCL2 expressing H37Rv/HCL2GFP cells
were counted from 8 different fields from different areas and percentage
was calculated.
Additional file 3: 10 fields from different areas were observed by
electron microscope and percentage of cell deformations was
calculated.
Additional file 4: Figure S4. (A) Intraperitoneal macrophages isolated
from mice were cultured and, 10 hours post-infection with H37Rv and
H37Rv/HCL2 strains in 1:10 ratio, were surface-stained with anti-CD11B,
CD11C antibodies followed by Annexin V staining for 40 min followed by
flow cytometry to assess pre apoptotic cells. HCL2 expression showed no
significant increase in Annexin V/apoptotic cells. The percentage of cells
expressing Annexin V among CD11B cells is shown with mean±STDEV.
Data shown here are representative of three independent experiments.
(B) GRAMM-X server based ESAT-6-HCL2 docking model. Pictorial
representation of ESAT-6 interacting with HCL2 as observed through
GRAMM-X docking server. (ESAT-6; Red, CFP10; Cyan, HCL2; Blue).
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